Anti-SIRPα antibodies as a potential new tool for cancer immunotherapy.

@article{Yanagita2017AntiSIRPAA,
  title={Anti-SIRPα antibodies as a potential new tool for cancer immunotherapy.},
  author={Tadahiko Yanagita and Yoji Murata and Daisuke Tanaka and S Motegi and Eri Arai and Edwin Widyanto Daniwijaya and Daisuke Hazama and Ken Washio and Yasuyuki Saito and Takenori Kotani and Hiroshi Ohnishi and P A Oldenborg and Noel Verjan Garcia and Masayuki Miyasaka and Osamu Ishikawa and Yae Kanai and Takahide Komori and Takashi Matozaki},
  journal={JCI insight},
  year={2017},
  volume={2 1},
  pages={e89140}
}
Tumor cells are thought to evade immune surveillance through interaction with immune cells. Much recent attention has focused on the modification of immune responses as a basis for new cancer treatments. SIRPα is an Ig superfamily protein that inhibits phagocytosis in macrophages upon interaction with its ligand CD47 expressed on the surface of target cells. Here, we show that SIRPα is highly expressed in human renal cell carcinoma and melanoma. Furthermore, an anti-SIRPα Ab that blocks the… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 12 times over the past 90 days. VIEW TWEETS
8 Citations
61 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 61 references

Alterations of the spindle checkpoint pathway in clinicopathologically aggressive CpG island methylator phenotype clear cell renal cell carcinomas

  • E Arai
  • Int J Cancer
  • 2015
Highly Influential
6 Excerpts

Similar Papers

Loading similar papers…